NF-κB与白血病的多药耐药  

Nuclear factor κappa-B and multidrug resistance in leukaemia

作　　者：骆蓉[1] 陈进伟[1] 

机构地区：[1]中南大学湘雅二医院血液科,长沙410011

出　　处：《国际病理科学与临床杂志》2006年第2期119-121,共3页Journal of International Pathology and Clinical Medicine

基　　金：湖南省科学技术厅科技计划项目(02SSY3069)

摘　　要：NF-κB是广泛存在于体内细胞中的重要核转录因子。除参与炎症、免疫等基因调节外,还在细胞增殖与凋亡的基因调控中起抗细胞凋亡作用。适度地抑制NF-κB的活性可以控制肿瘤细胞多药耐药性的产生,对提高白血病的化疗效果有着十分重要的临床意义。Multidrug resistance （MDR） is a mostly causation of chemotherapy failing in leukaemia. Nuclear factor Kappa-B （NF-κB） is an important nuclear transcription gene which consists in cells abroadly in vivo. NF-κB are not only concerned with regulation of inflammation and immunity genes, but also resist in apoptosis via adjusting the gene of cell proliferation and cell process death. Anticancer drug killed the tumour cell, at the same time also activated NF-κB, which lead to the tumour cell drug resistance through increasing the expression of MDR gene. To restrain the activity of NF-κB moderately can control multidrng resistance of tumour cell, and improve chemotherapy effect in leukaemia.

关 键 词：白血病 核转录因子 多药耐药 抑制 

分 类 号：R733.7[医药卫生—肿瘤]